- Home
- NDLS vs LTRN Comparison
NDLS vs LTRN Comparison
Compare NDLS & LTRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NDLS
- LTRN
- Stock Information
- Founded
- NDLS 1995
- LTRN 2013
- Country
- NDLS United States
- LTRN United States
- Employees
- NDLS N/A
- LTRN N/A
- Industry
- NDLS Restaurants
- LTRN Biotechnology: Pharmaceutical Preparations
- Sector
- NDLS Consumer Discretionary
- LTRN Health Care
- Exchange
- NDLS Nasdaq
- LTRN Nasdaq
- Market Cap
- NDLS 33.2M
- LTRN 36.0M
- IPO Year
- NDLS 2013
- LTRN 2020
- Fundamental
- Price
- NDLS $0.67
- LTRN $3.81
- Analyst Decision
- NDLS Buy
- LTRN Strong Buy
- Analyst Count
- NDLS 2
- LTRN 1
- Target Price
- NDLS $3.00
- LTRN $25.00
- AVG Volume (30 Days)
- NDLS 170.0K
- LTRN 73.6K
- Earning Date
- NDLS 11-05-2025
- LTRN 11-06-2025
- Dividend Yield
- NDLS N/A
- LTRN N/A
- EPS Growth
- NDLS N/A
- LTRN N/A
- EPS
- NDLS N/A
- LTRN N/A
- Revenue
- NDLS $494,752,000.00
- LTRN N/A
- Revenue This Year
- NDLS $1.19
- LTRN N/A
- Revenue Next Year
- NDLS N/A
- LTRN N/A
- P/E Ratio
- NDLS N/A
- LTRN N/A
- Revenue Growth
- NDLS N/A
- LTRN N/A
- 52 Week Low
- NDLS $0.55
- LTRN $2.55
- 52 Week High
- NDLS $1.74
- LTRN $6.12
- Technical
- Relative Strength Index (RSI)
- NDLS 40.55
- LTRN 39.37
- Support Level
- NDLS $0.66
- LTRN $3.74
- Resistance Level
- NDLS $0.76
- LTRN $4.26
- Average True Range (ATR)
- NDLS 0.03
- LTRN 0.31
- MACD
- NDLS 0.00
- LTRN -0.06
- Stochastic Oscillator
- NDLS 18.18
- LTRN 7.59
About NDLS Noodles & Company
Noodles & Co is a restaurant concept offering lunch and dinner within the fast-casual segment of the restaurant industry. The company's menu includes a variety of cooked-to-order dishes, including noodles and pasta, soups, salads and appetizers. The company also provides dining, pick-up and delivery services.
About LTRN Lantern Pharma Inc.
Lantern Pharma Inc is an AI company transforming the cost, pace, and timeline of oncology drug discovery and development. Its proprietary AI and machine learning (ML) platform, RADR, uses oncology-focused data points and advanced ML algorithms to solve billion-dollar, real-world problems in cancer drug development. The group's growing pipeline of precision therapies has been accelerated using AI and input from world-class scientific advisors and collaborators.